



**The Executive Office of Health & Human Services
Center for Operations and Pharmacy Management**

Pharmacy and Therapeutics Committee Meeting Minutes

Tuesday August 28, 2012

8:00 AM

**Hilton Garden Inn
One Thurber Street/Jefferson Blvd
Warwick, Rhode Island**

P & T Members Present: Greg Allen, MD
Scott Campbell, RPh
Dave Feeny, RPh. Chairperson
Chaz Gross, NAMI
L. McIntyiere Johnston, MD
Richard Wagner, MD

P & T Members Absent: Ray Maxim, MD OHHS
Matt Salisbury, MD
Kristina Ward, PharmD
Rita Marcoux RPh, Co-Chairperson

Others Present: Ann Bennett (HP Enterprise Services)
Karen Mariano (HP Enterprise Services)
Kathryn Novak (Magellan Medicaid Administration)
Joe Paradis, RPh (HID)

The meeting was called to order by the Chairperson once a quorum was in attendance - 8:25 am.

The June 2012 meeting minutes were reviewed and by vote were accepted as presented with minor grammatical changes.

Dave Feeny announced that Mack Johnston would be retiring after this meeting. A recommendation was made that Tracey Cohen, Medical Director of NHP take his place at that time. A motion was made and passed unanimously, to accept Dr Cohen as a committee member starting in December 2012.

Public testimony included the following presentations: Preeti Kanojia (Health Economics and Outcomes Research/Janssen Scientific) and Reese Patel (Medical Liason, UCB) Neil Morata (Medical Affairs, Pfizer), Christiane Arciver (Medical Director, Merck), James Ader (Regional General Manager, Genentech), Mario Alfonso (Medical Liason, Astellis Pharma), Vic Patel (INCIVIK REPRESENTATIVE)

Magellan Medicaid Administration presented the following categories for therapeutic class reviews with discussion from the committee.

- 1. Androgenic Agents – Androderm goes to non preferred (NP). Suggested not to grandfather patients. Motion made to accept the recommendations & passes unanimously.**
- 2. Antiemetic/Antivertigo Agents – Emend goes to NP status. Motion made to accept the recommendations & passes unanimously.**
- 3. Anti-virals, Herpes – Oral Question what is the average cost per patient for valcyclovir. Kathy Novak will get back to Rick Wagner. Motion made to accept the recommendations & passes unanimously.**
 - a. Oral - Motion made to accept the recommendations & passes unanimously**

- b. Topicals - Motion made to accept the recommendations & passes unanimously.
- 4. BPH Treatments Cialis has been approved for BPH; new generic alfuzosin ER for Uroxatral. Motion made to accept the recommendations & passes unanimously.
- 5. Bladder Relaxants – No changes in the category. What is the incidence rate of glaucoma ?
- 6. Cytokine and CAM Antagonists – Guidelines are updates; please see page 5 of the TCR for the details. Orencia now available as an SQ, post loading dose of IV. Category is being expanded to include Remicade. Updated BBW/labeling for Humira. Motion made to accept the recommendations & passes unanimously.
- 7. Erythropoiesis Stimulating Proteins – new synthetic ESA, Erythropeitins-Omntys (should see on the medical claims) These claims should be on the medical side not on the POS Rx side of the claims. . Motion made to accept the recommendations & passes unanimously.
- 8. Hepatitis C Agents – updates to drug interaction updates re: statins and protease inhibitors. Guidelines support triple therapy in genotype 1. . Motion made to accept the recommendations & passes unanimously. Recommend DUR look at this with intent to treat and look at adherence over time and report back to committee
- 9. Immunomodulators, Atopic Dermatitis – Preferred is Elidel with a fx of at least one topical anti-inflam steroid in the past 3 months. There is a significant difference in cost of the agents. If someone is stabilized then leave patients as grandfathered. . Motion made to accept the recommendations & passes unanimously.
- 10. NSAIDS – review currently expanded to include all of the oral agents and topicals. Recommending a category expansion. . Motion made to accept the recommendations & 1 absention, 1 no and 3 to passes.
- 11. Ophthalmic Agents
 - a. Antibiotics – no new agents in category. . Motion made to accept the recommendations & passes unanimously.
 - b. Allergic Conjunctivitis – recommendation to include cormolyn sodium in the category. Motion made to accept the recommendations & passes unanimously
 - c. Glaucoma Motion made to accept the recommendations & passes unanimously
- 12. Otic Antibiotics – one new generic ofloxacin. Motion made to accept the recommendations & passes unanimously
- 13. Pancreatic Enzymes – new product Pertzye. Motion made to accept the recommendations & passes unanimously
- 14. Phosphate Binders – no new products. Motion made to accept the recommendations & passes unanimously

The dates identified for the remaining 2012 meeting is: December 11th. Motion made to review the bylaws at the December 2012 meeting.

The dates identified for the 2013 meetings are: April 2nd, June 4th, August 27th and December 10th. As always, the meetings will begin at 8:00 AM.

The meeting adjourned at 9:50 AM.